BTIG Research Issues Positive Forecast for Innate Pharma (NASDAQ:IPHA) Stock Price

Key Points

• BTIG Research raised Innate Pharma’s price target to $9.00 from $8.00 and maintained a “Buy” rating, implying 318.6% upside from the prior close.
• Analyst sentiment is broadly positive: five analysts rate the stock a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average target price of $6.67.
• Despite improving long-term earnings expectations and recent institutional purchases, HC Wainwright lowered its 2026 and 2027 EPS forecasts, pointing to deeper near-term losses.

Innate Pharma (NASDAQ:IPHA - Get Free Report) had its price target hoisted by equities researchers at BTIG Research from $8.00 to $9.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's price objective would suggest a potential upside of 318.60% from the stock's previous close.

Other equities research analysts also recently issued reports about the stock. Leerink Partners raised shares of Innate Pharma from a "market perform" rating to an "outperform" rating and set a $4.00 price target for the company in a report on Tuesday. Weiss Ratings upgraded Innate Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, June 26th. UBS Group reiterated a "buy" rating on shares of Innate Pharma in a research report on Tuesday. Citigroup raised shares of Innate Pharma from a "buy" rating to an "outperform" rating in a research report on Tuesday. Finally, HC Wainwright lifted their price target on shares of Innate Pharma from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $6.67.

Innate Pharma Stock Down 3.2%

IPHA stock opened at $2.15 on Wednesday. The company has a 50-day simple moving average of $1.80 and a 200 day simple moving average of $1.67. Innate Pharma has a fifty-two week low of $1.17 and a fifty-two week high of $2.62.

Hedge Funds Weigh In On Innate Pharma

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of Innate Pharma in the fourth quarter worth $162,000. Millennium Management LLC bought a new stake in shares of Innate Pharma during the 4th quarter worth about $36,000. Finally, OLD Mission Capital LLC acquired a new stake in shares of Innate Pharma in the fourth quarter valued at approximately $50,000. Institutional investors own 0.16% of the company's stock.

Key Innate Pharma News

Here are the key news stories impacting Innate Pharma this week:

• Positive Sentiment: Strategic Sobi partnership: Innate Pharma and Swedish Orphan Biovitrum (Sobi) agreed to advance lacutamab into a pivotal Phase 3 trial for a rare form of T-cell lymphoma. The deal is expected to provide financing and development support for the cancer therapy, reducing some execution and funding risk. Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
• Positive Sentiment: Analyst upgrade: Leerink Partners raised Innate Pharma from “market perform” to “outperform” and assigned a $4.00 price target, signaling considerable potential upside from recent trading levels.
• Positive Sentiment: Long-term earnings outlook improved: HC Wainwright maintained its “Buy” rating and $7.00 target while raising its FY2028 EPS estimate to $(0.15), FY2029 to $0.23, and FY2030 to $0.58. The revisions imply a path to profitability beginning in FY2029.
• Neutral Sentiment: Short-interest data is not meaningful: Reported short interest remained at zero shares, with a zero-day short-interest ratio. This provides little indication of trading pressure because the reported figures show no meaningful short position.
• Negative Sentiment: Near-term earnings estimates were cut: HC Wainwright lowered its FY2026 EPS forecast to $(0.79) from $(0.65) and FY2027 to $(0.59) from $(0.51). These deeper projected losses may be weighing on the stock despite the improved longer-term outlook.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source